 Nkarta Inc NASDAQ: NKTX has collaborated with CRISPR Therapeutics AGNASDAQ: CRSP to co-develop and commercialize two CAR-NK therapies, in addition to an NKT program. The companies will split all the RD costs and any worldwide profits, 5050. 